High serum cholesterol levels are associated with death from coronary heart disease and statin therapy has been demonstrated to effectively lower low-density lipoprotein (LDL) cholesterol and reduce coronary events in broad sections of the population. Recently, the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) randomized 17 802 apparently healthy individuals, with levels of LDL cholesterol below current treatment thresholds but with elevated levels of high-sensitivity C-reactive protein, to rosuvastatin 20 mg daily, or placebo. At a median follow-up of almost 2 years, compared to placebo, rosuvastatin treatment was associated with a significant reduction in the incidence of major cardiovascular or cerebrovascular events, that is, almost twice the magnitude found in previous statin trials. Such a noteworthy finding is discussed herein

Sgueglia, G. A., Crea, F., The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?, <<JOURNAL OF CARDIOVASCULAR MEDICINE>>, 2011; (12): 66-70. [doi:10.2459/JCM.0b013e32834102ab] [http://hdl.handle.net/10807/3056]

The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?

Sgueglia, Gregory Angelo;Crea, Filippo
2011

Abstract

High serum cholesterol levels are associated with death from coronary heart disease and statin therapy has been demonstrated to effectively lower low-density lipoprotein (LDL) cholesterol and reduce coronary events in broad sections of the population. Recently, the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) randomized 17 802 apparently healthy individuals, with levels of LDL cholesterol below current treatment thresholds but with elevated levels of high-sensitivity C-reactive protein, to rosuvastatin 20 mg daily, or placebo. At a median follow-up of almost 2 years, compared to placebo, rosuvastatin treatment was associated with a significant reduction in the incidence of major cardiovascular or cerebrovascular events, that is, almost twice the magnitude found in previous statin trials. Such a noteworthy finding is discussed herein
2011
Inglese
Sgueglia, G. A., Crea, F., The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?, <<JOURNAL OF CARDIOVASCULAR MEDICINE>>, 2011; (12): 66-70. [doi:10.2459/JCM.0b013e32834102ab] [http://hdl.handle.net/10807/3056]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/3056
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact